investor conference

Biodesix reports 24% full-year 2025 revenue growth to $88.5M, with Q4 surging 41% YoY. Company expects adjusted EBITDA positivity and plans investor roadshow.

Supernus Pharmaceuticals will present at three major healthcare conferences in March 2026, updating investors on strategic initiatives and operational progress.

Nasus Pharma CEO presents clinical pipeline at three major healthcare conferences in February-March, showcasing NS002 intranasal epinephrine for anaphylaxis treatment.

Micron reaffirmed its HBM4 chip timeline with no delays, addressing investor concerns about its ability to meet AI memory demand as competition intensifies.

Orchestra BioMed will present at two major healthcare investor conferences in March 2026, engaging with institutional investors on strategy and clinical progress.

4DMT will present pipeline progress at three major healthcare conferences in March 2026, showcasing late-stage programs including 4D-150 for retinal disease and 4D-710 for cystic fibrosis.

Protara Therapeutics will present TARA-002 Phase 2 interim data at ASCO GU Symposium, showcasing results for BCG-unresponsive bladder cancer treatment.

Sinclair executives will present at two major finance conferences in March 2026, discussing strategic direction and financial performance with investors and analysts.

Lumexa Imaging leadership will present at three major healthcare investment conferences in March 2026, providing investors direct access during sector growth.

Axogen will present at three major healthcare conferences in March 2026, conducting investor meetings and showcasing its business case to institutional investors and analysts.

Datatec to present at AI & Technology Conference February 19th, showcasing strategic growth through recent acquisitions in managed security services and Eastern European cybersecurity distribution.